E
Tvardi Therapeutics, Inc. TVRD
$3.75 -$0.16-4.09% NASDAQ
Recommendation
Prev Close
$3.91
Volume
138,681
Avg Vol (90D)
215,080
Market Cap
$36.68M
Dividend & Yield
--
52-Week Range
$3.78 - $43.65
P/E (TTM)
--
EPS (TTM)
-$5.08
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
11/30/2025 - PR Newswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
11/29/2025 - Globe Newswire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
11/21/2025 - PR Newswire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
11/20/2025 - Globe Newswire
Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
11/18/2025 - Zacks Investment Research
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/18/2025 - GuruFocus
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/18/2025 - Business Wire
Tvardi Therapeutics Faces Financial Hurdles Amidst Ongoing Product Development Challenges
11/16/2025 - TipRanks Financial Blog
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
11/14/2025 - PR Newswire
Tvardi Therapeutics (TVRD) Gets a Hold from Piper Sandler
11/14/2025 - TipRanks Financial Blog
Barclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD)
11/14/2025 - TipRanks Financial Blog
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
11/13/2025 - GuruFocus
Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)
11/13/2025 - The Fly
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
11/13/2025 - Business Wire
How The Pieces Add Up: IWN Targets $214
11/13/2025 - ETF Channel
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. ...
11/12/2025 - GuruFocus
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
11/12/2025 - Globe Newswire
TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
11/9/2025 - Globe Newswire
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
11/6/2025 - Business Wire
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. ...
11/5/2025 - GuruFocus
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
11/5/2025 - Globe Newswire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
11/4/2025 - Globe Newswire
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
11/4/2025 - GuruFocus
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives Average Recommendation of "Hold" from Analysts
11/4/2025 - Ticker Report
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
11/4/2025 - Business Wire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$29.87M
EBIT (TTM)
-$29.96M
Net Income (TTM)
-$23.65M
Balance Sheet
Total Assets (Q)
$39.02M
Total Debt (Q)
$228.00K
Total Liabilities (Q)
$11.16M
Book Value Per Share (Q)
$2.97
Cash Flow
Cash from Operations (TTM)
-$22.65M
Cash from Investing (TTM)
-$15.08M
Cash from Financing (TTM)
$49.71M
Net Change in Cash (TTM)
$11.98M
Filings
Filing Date
Thursday, November 13, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of May 25 and 29 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-1.83%
30-Day Total Return
-39.22%
60-Day Total Return
-87.36%
90-Day Total Return
-85.86%
Year to Date Total Return
-79.45%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Nov 21, 2025 - $3.78
52-week High
Oct 10, 2025 - $43.65
Valuation
Market Cap
$36.68M - Nano Cap
Enterprise Value
$449.06K
Price/Sales (TTM)
--
Price/Book (Q)
1.32
Dividends and Shares
Shares Outstanding
9.38
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
tvarditherapeutics.com
Phone Number
713 489 8654
Address
3 Sugar Creek Center Boulevard
Sugar Land, TX 77478
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases... more
NASDAQ 12/02/2025 4:00PM Eastern Quotes delayed